Skip to main content
. Author manuscript; available in PMC: 2013 Aug 23.
Published in final edited form as: Am Heart J. 2011 May;161(5):972–978. doi: 10.1016/j.ahj.2011.01.017

Table I.

Baseline characteristics of participants with and without PAD

Overall
(N = 959)
Subjects
with PAD
(n = 172)
Subjects
without
PAD
(n = 787)
P
Demographic data
  Age (y), mean* 63 ± 9 65 ± 8 62 ± 9 .0005
  Men/women (%) 71/29 74/26 71/29 .4232
  Body mass index (kg/m2), mean* 30 ± 6 29 ± 5 30 ± 6 .0167
  Systolic blood pressure* 133 ± 15 133 ± 15 133 ± 15 .9834
  Diastolic blood pressure* 78 ± 9 76 ± 10 78 ± 9 .0163
  Heart rate* 67 ± 11 68 ± 12 67 ± 10 .0736
Risk factors (%)
  Diabetes 49 35 52 <.0001
  Hypertension 74 75 74 .7697
  Dyslipidemia 61 65 60 .2871
  Current smoking 14 19 13 .0265
Medical history (%)
  CHD 54 61 52 .0163
  PAD 18 100 0
  Stroke or transient ischemic attack 6 12 5 .0007
  No documented vascular disease 39 0 48
Concomitant medications (%)
  Antiplatelet 83 84 82 .4287
  Atorvastatin 100 100 100
  ACE inhibitor or ARB 68 67 68 .9136
  β-Blocker 48 50 48 .6418
  Thiazolidinedione 10 8 10 .4255

ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker.

*

Presented as arithmetic mean ± SD.

Denotes diabetes requiring pharmacotherapy.

Refers to patients with Framingham Risk Score >20%.